Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Part of paid clinical trials in Hackensack, New Jersey.

Sponsor
Impact Therapeutics, Inc.
Study ID
NCT05269316
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IMP9064 — DRUG
    IMP9064 Monotherapy administered for 21 days

Study Details

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

Key Dates

Start date
Feb 11, 2022
Status verified
Aug 2024
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
61 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: IMP9064 Monotherapy
    Dose-escalation IMP9064 administered orally on empty stomach once/twice daily

Primary Outcome Measure

Incidence of adverse events (Safety and Tolerability) [ Time Frame: 11 months ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Hackensack University Medical Center PARTNERHackensackNew Jersey07601-
Mount SinaiNew YorkNew York10029-
Greenville Hospital System University Medical Center (ITOR)GreenvilleSouth Carolina29605-
Mary Crowley Cancer Research CentersDallasTexas75251-

Find similar trials in Hackensack, NJ

By research site
Hackensack University Medical Center PARTNER· Hackensack, NJMount Sinai· New York, NYGreenville Hospital System University Medical Center (ITOR)· Greenville, SCMary Crowley Cancer Research Centers· Dallas, TX

Related Studies